Celldex Therapeutics Inc


Prices are adjusted according to historical splits.

Celldex Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$1.61 billion
Book Value:
Revenue TTM:
$3.15 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Celldex Therapeutics Inc had its IPO on 2008-03-10 under the ticker symbol CLDX.

The company operates in the Healthcare sector and Biotechnology industry. Celldex Therapeutics Inc has a staff strength of 148 employees.

Stock update

Shares of Celldex Therapeutics Inc opened at $27.5 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $27.17 - $28.04, and closed at $27.63.

This is a +0.36% increase from the previous day's closing price.

A total volume of 246,495 shares were traded at the close of the day’s session.

In the last one week, shares of Celldex Therapeutics Inc have slipped by -4.1%.

Celldex Therapeutics Inc's Key Ratios

Celldex Therapeutics Inc has a market cap of $1.61 billion, indicating a price to book ratio of 5.0657 and a price to sales ratio of 1935.1115.

In the last 12-months Celldex Therapeutics Inc’s revenue was $3.15 million with a gross profit of $-79901000 and an EBITDA of $-112963000. The EBITDA ratio measures Celldex Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Celldex Therapeutics Inc’s operating margin was -3675.37% while its return on assets stood at -19.33% with a return of equity of -33.86%.

In Q1, Celldex Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 455.7%.

Celldex Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.64 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celldex Therapeutics Inc’s profitability.

Celldex Therapeutics Inc stock is trading at a EV to sales ratio of 1326.4524 and a EV to EBITDA ratio of -16.2809. Its price to sales ratio in the trailing 12-months stood at 1935.1115.

Celldex Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$324.52 million
Total Liabilities
$15.22 million
Operating Cash Flow
$52.57 million
Capital Expenditure
Dividend Payout Ratio

Celldex Therapeutics Inc ended 2023 with $324.52 million in total assets and $0 in total liabilities. Its intangible assets were valued at $324.52 million while shareholder equity stood at $302.74 million.

Celldex Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $15.22 million in other current liabilities, 47000.00 in common stock, $-1285293000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $54.12 million and cash and short-term investments were $278.39 million. The company’s total short-term debt was $1,493,000 while long-term debt stood at $0.

Celldex Therapeutics Inc’s total current assets stands at $289.60 million while long-term investments were $0 and short-term investments were $224.26 million. Its net receivables were $1.31 million compared to accounts payable of $3.37 million and inventory worth $0.

In 2023, Celldex Therapeutics Inc's operating cash flow was $52.57 million while its capital expenditure stood at $585000.

Comparatively, Celldex Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Celldex Therapeutics Inc stock is currently trading at $27.63 per share. It touched a 52-week high of $48.4 and a 52-week low of $48.4. Analysts tracking the stock have a 12-month average target price of $66.33.

Its 50-day moving average was $32.49 and 200-day moving average was $37.11 The short ratio stood at 9.21 indicating a short percent outstanding of 0%.

Around 30.7% of the company’s stock are held by insiders while 10554.8% are held by institutions.

Frequently Asked Questions About Celldex Therapeutics Inc

The stock symbol (also called stock or share ticker) of Celldex Therapeutics Inc is CLDX

The IPO of Celldex Therapeutics Inc took place on 2008-03-10

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company’s proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.


Perryville III Building, Hampton, NJ, United States, 08827